Laboratory Corporation of America Holdings

Spending by Year

Lobbying Firms

What They Lobby For

• Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests including the discussion draft of Diagnostic Accuracy and Innovation Act (DAIA); Medicare reimbursement levels for laboratory services and reforms to Clinical Laboratory Fee Schedule; and federal policy relating to drug development.
• Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA), FDAs technical assistance on DAIA, and the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development
• Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule; federal policy relating to drug development
• Healthcare issues related to clinical laboratories; FDA oversight of laboratory developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; Medicare coverage and reimbursement levels for laboratory services and reforms to the Clinical Laboratory Fee Schedule including provisions contained in H.R. 3584, the Laboratory Access for Beneficiaries (LAB) Act ; federal policy relating to drug development; federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220); federal policy relating to subject matter eligibility for patents of laboratory tests.
• Healthcare issues related to clinical laboratories; FDA oversight of laboratory-developed tests, including the discussion draft of the Verifying Accurate Leading-edge IVCT Development (VALID) Act; H.R. 3584/ S. 3049, the Laboratory Access for Beneficiaries (LAB) Act, provisions relating to modification of reporting of private-sector payments used to establish Medicare rates for clinical diagnostic laboratory tests and directing a third party study and report including recommendations on private-sector payment data collection requirements and Medicare rate methodologies. H.R. 1865, the Further Consolidated Appropriations Act, Section 105 of Division N, provisions incorporating the LAB Act; Federal policy relating to drug development; and Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220).
• Healthcare issues related to clinical laboratories; H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy relating to FDA oversight of pharmacogenetic tests, including potential inclusion in the Fiscal Year 2021 Agriculture-FDA appropriations bill; H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, funding for child care for laboratory personnel, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed; H.R. 3584/ S. 3049, the Laboratory Access for Beneficiaries (LAB) Act, provisions relating to modification of reporting of private-sector payments used to establish Medicare rates for clinical diagnostic laboratory tests and directing a third party study and report including recommendations on private-sector payment data collection requirements and Medicare rate methodologies. H.R. 1865, the Further Consolidated Appropriations Act, Section 105 of Division N, provisions incorporating the LAB Act; Federal policy relating to drug development; and Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220) including potential inclusion in the Fiscal Year 2021 Labor-HHS appropriations bill.
• Healthcare issues related to clinical laboratories; H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; H.R. 266, the Paycheck Protection Program and Healthcare Enhancement Act, Pub. L. 116-139, provisions relating to COVID-19 provider emergency funding, lab capacity funding, and funding of lab services to the uninsured; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed; Federal policy relating to drug development, including potential legislation known as Cures 2.0; Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill.
• Healthcare issues related to clinical laboratories; H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Paycheck Protection Program and Healthcare Enhancement Act, Pub. L. 116-139, provisions relating to COVID-19 provider emergency funding, lab capacity funding, and funding of lab services to the uninsured; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests, Medicare reimbursement for clinical laboratory tests, and emergency funding for COVID-19 related revenue losses and expenses not otherwise reimbursed; H.R. 7059, the Coronavirus Provider Protection Act and H.R. 7528, the Get America Back to Work Act, provisions relating to limitation of liability for COVID-19 related services; Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing; Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation; Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill.
• Healthcare issues related to clinical laboratories; H.R. 6102/S. 3404, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing; H.R. 8496, the SPEEDY COVID-19 Test Act, provisions relating to varying Medicare reimbursement for COVID-19 tests based on result delivery time; Federal policy relating to funding COVID-19 surveillance and transmission studies using next generation sequencing, including potential legislation; Federal policy relating to drug development, including potential legislation known as Cures 2.0; Federal policy relating to anti-kickback requirements in Section 8122 of the Support for Patients and Communities Act, Pub. L. 115-271 (18 U.S.C. 220), including potential legislation as part of the Fiscal Year 2021 Commerce-Justice-Science appropriations bill and the Fiscal Year 2021 Labor-HHS appropriations bill; and Federal policy relating to FDA oversight of pharmacogenetic tests, including potential legislation as part of the Fiscal Year 2021 Agriculture-FDA appropriations bill; and Title I of Division BB of the Consolidated Appropriations Act of 2021, Pub. L. 116-260, provisions relating to surprise billing.
• Legislation relating to FDA oversight of laboratory-developed test; Federal policy related to implementation of Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing; Federal policy relating to drug development, including potential legislation known as Cures 2.0; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; and Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93.

Related Investigations

Explore More